Nucor earnings beat by $0.08, revenue fell short of estimates
LONDON - Mid Yorkshire Teaching NHS Trust has been shortlisted for the HSJ Patient Safety Awards following implementation of a nasal decolonization technology that reduced surgical site infections by 71% over six months.
The trust used Ondine Biomedical’s Steriwave technology for patients undergoing hip and knee replacement surgeries, according to a press release issued Thursday. The implementation reportedly led to cost savings and improved patient outcomes.
Steriwave is described as a non-invasive light-activated antimicrobial therapy that targets pathogens in the nose. The treatment involves applying a photosensitive agent to the nostrils followed by illumination with red light.
"Being named a finalist is a testament to the hard work and dedication of our team," said Dr. Stuart Bond, Consultant Antimicrobial Pharmacist and Director of Innovation at Mid Yorkshire Teaching NHS Trust.
The Health Service Journal’s Patient Safety Awards recognize healthcare teams working to improve safety across the UK healthcare sector. Winners will be announced later this year.
Steriwave works against bacteria, viruses, and fungi without contributing to antimicrobial resistance, according to the company statement. The technology has reportedly generated interest from other NHS hospitals amid rising antibiotic resistance concerns.
Ondine Biomedical is listed on the AIM market of the London Stock Exchange (LON:LSEG) under the ticker AIM:OBI.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.